Trending
Breaking News from August 19, 2026, The New York Times: "A New mRNA Vaccine Could Prevent Skin Cancer From Returning."
A vaccine? For cancer? For melanoma -- the deadliest form of skin cancer? How can this even work?
To explain it to myself, and to you, I turned to what I know about wars.
Imagine a general who has just been notified that a foreign enemy has invaded his territory. He orders the immediate, complete, and utter elimination of the opposing troops.
The first step is identification. Who is a friend and who is a foe?
The distinction may be difficult. But you may get lucky. Your troops, for example, are all clean-shaven, scalp and face alike, while the enemy soldiers grow beards and are proud of long mustaches that curl at the ends--Salvador Dalí style.
A smart general would spread the news quickly. He might distribute pictures of the enemy, beards and mustaches included. Or, better yet, stick the head of their leader on a spike and tell his troops: This is what your enemy looks like. Seek. Find. Kill.
The idea behind the melanoma vaccine is somewhat similar.
Cancer cells are different from normal cells. Their DNA has accumulated mutations, and some of those mutations cause the cancer cells to make abnormal proteins. Bits of these proteins, called neoantigens, can act like identifying marks--the molecular equivalent of our enemy's long, curled mustache.
Scientists can use those identifying marks to teach the immune system what to look for.
How?
First, doctors surgically remove the melanoma. Scientists then sequence the tumor's DNA and identify mutations that are likely to produce distinctive neoantigens. From those, they select a group of the best targets.
Then they manufacture a personalized mRNA vaccine containing instructions for making those targets.
In other words, every vaccine is custom-made for one patient and one tumor.
After the vaccine is injected, cells use the mRNA instructions to make small amounts of these telltale cancer proteins. The immune system sees them and learns: This is what the enemy looks like.
Armies of killer T cells are recruited. They multiply with a singular mission: find cells displaying those same identifying marks and destroy them.
If microscopic melanoma cells remain somewhere in the body after surgery, the hope is that these newly trained immune cells will recognize them and eliminate them before the cancer has a chance to return.
There is one important distinction here. This isn't a vaccine like the measles or flu vaccine, given to healthy people to prevent them from developing the disease. It is a therapeutic cancer vaccine designed for people who have already had melanoma. Its purpose is to prevent the cancer from coming back.
So, how well does it work?
At the 2026 annual meeting of the American Society of Clinical Oncology, researchers presented five-year results from a randomized trial. Patients with high-risk melanoma whose tumors had been completely removed received either Keytruda (pembrolizumab), an established immunotherapy drug, or Keytruda plus the personalized mRNA vaccine.
After five years, adding the vaccine reduced the relative risk of the melanoma recurring or the patient dying by 49 percent. It reduced the relative risk of distant metastasis or death by 59 percent.
And in August, Moderna and Merck announced another important milestone: a much larger Phase 3 trial also found that adding the vaccine significantly reduced melanoma recurrence and distant spread compared with Keytruda alone.
Can the same idea work against other cancers?
Possibly.
Melanoma is particularly well suited to this approach because melanoma cells often carry many mutations, providing the immune system with plenty of potential identifying marks. Other cancers may be more difficult. The success of a cancer vaccine depends not only on finding mutations, but also on the biology of the tumor and how well the immune system can recognize and attack it.
Researchers are now testing personalized mRNA cancer vaccines in several other cancers, including lung, bladder, kidney, pancreatic, and stomach cancers.
Whether they will work as well remains to be seen.
But the idea is remarkably simple.
Find something that distinguishes the enemy from everyone else. Show it to the immune system. Then let the immune system hunt it down.
As long as a tumor leaves behind a distinctive genetic fingerprint -- a long mustache, a distinguished beard--we may be able to teach the immune system what the enemy looks like.